Clinical trials: African Americans
COVID-19
The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin
This study is a multi-center, randomized, double blinded, prospective, placebo controlled study. Patients upon diagnosis of COVID-19 (Corona Virus Disease-19) will be eligible to participate in the study.
- Trial name
- NCT04601077
- Testing
- Nitric Oxide lozenges, 30 mg
- Where
- United States
- Volunteers
- 524 people
- Sponsor
- Nitric Oxide Innovations LLC
Hypertension
Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension
The main purpose of this study is to evaluate the effects of Nebivolol and Hydrochlorothiazide on blood pressure in African Americans with high blood pressure.
- Trial name
- NASAA (NCT00999752)
- Testing
- Nebivolol, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- InVasc Therapeutics, Inc.
Diabetes Mellitus, Type 2
Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study
Study of linagliptin vs. placebo in Black/African American patients with T2DM with a MTT sub-study
- Trial name
- NCT01194830
- Testing
- Linagliptin
- Where
- 93 sites in United States
- Volunteers
- 234 people
- Sponsor
- Boehringer Ingelheim
Systemic Lupus Erythematosus
Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients of black race with systemic lupus erythematosus (SLE; lupus).
- Trial name
- EMBRACE (NCT01632241)
- Testing
- Belimumab 10 mg/kg plus standard therapy, Standard therapy
- Where
- 96 sites in United States, Brazil and 4 more
- Volunteers
- 503 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD
Study CTQJ230A12303 is a randomized, double-blind placebo-controlled, Phase IIIb study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) 80 mg s.c. QM compared with placebo s.c.
- Trial name
- NCT06267560
- Testing
- TQJ230
- Where
- 96 sites in United States, Puerto Rico
- Volunteers
- 422 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Effects of Amlodipine/Benazepril in the Hypertensive African-American Population With Type 2 Diabetes Mellitus
This study evaluated the efficacy and safety of amlodipine/benazepril compared with that of enalapril in the treatment of hypertension in African-American patients with type 2 diabetes.
- Trial name
- NCT00367978
- Testing
- Amlodipine/benazepril
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Novartis
Hypertension
Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension
The purpose of the study is to evaluate the BP-lowering efficacy of the combination of aliskiren and amlodipine, as initial therapy, compared to amlodipine monotherapy in African American patients with Stage II hypertension.
- Trial name
- AACESS (NCT00853957)
- Testing
- Aliskiren/Amlodipine, Amlodipine
- Where
- 9 sites in United States
- Volunteers
- 443 people
- Sponsor
- Novartis
Asthma
A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.
The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration, FDA) in the African American population.
- Trial name
- NCT00419952
- Testing
- Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI
- Where
- 122 sites in United States
- Volunteers
- 742 people
- Sponsor
- AstraZeneca
Mental Health Wellness 1, Preterm Birth
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
This randomized controlled trial will test an intervention called the Mastery Lifestyle Intervention (the MLI) that was developed from data of 1000+pregnant Hispanic women related to risks of preterm birth.
- Trial name
- MLI (NCT05012072)
- Testing
- The Mastery Lifestyle Intervention
- Where
- United States
- Volunteers
- 238 people
- Sponsor
- Microgen LLC
Hypertension
Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans
The purpose of the study is to evaluate the efficacy and safety of a fixed dose combination of aliskiren HCTZ versus amlodipine in African American patients with Stage 2 hypertension.
- Trial name
- ATLAAST (NCT00739596)
- Testing
- Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks, Amlodipine: 8 weeks
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- Novartis Pharmaceuticals
Women, Community Health Workers
Supplying Useful Perimenopause Through Post-menopause Online Resources and Tools
The goal of the study is to examine the extent to which exposure to the SUPPORT prototype increases community health workers' (CHWs) knowledge, skills, and self-efficacy to conduct effective outreach to minority women…
- Conditions
- Women, Community Health Workers, Health, Menopause
- Trial name
- SUPPORT (NCT07589335)
- Testing
- Lessons 1-4 for SUPPORT course
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- KDH Research & Communication
HIV-1-infection
mHealth for ART Adherence by HIV+ African Americans
The objective of this grant is to create and test a mobile app to support ART adherence among HIV+ African American adults.
- Trial name
- NCT04557332
- Testing
- On the Dot Mobile app
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Environment and Health Group, Inc.
Breast Cancer
A Real-World Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer Patients
The aim of this study was to assess real-world treatment patterns and tolerability of ribociclib among patient populations historically underrepresented in clinical trials - specifically older adults and Black/African American…
- Trial name
- NCT07760714
- Where
- United States
- Volunteers
- 945 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Graft Versus Host Disease
Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy
The purpose of this study is to measure safety and efficacy of oral belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander male and female participants with cGVHD…
- Trial name
- NCT05567406
- Testing
- Belumosudil
- Sponsor
- Kadmon, a Sanofi Company
Stable Coronary Artery Disease
A Pharmacodynamic Study With Ticagrelor in African American Patients
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in African American patients with stable coronary artery disease.
- Trial name
- NCT01523392
- Testing
- Ticagrelor, Clopidogrel
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Hypertension
24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension
This trial is designed to investigate the efficacy and safety of empagliflozin compared with placebo in hypertensive black/African Americans with type 2 Diabetes Mellitus.
- Trial name
- NCT02182830
- Testing
- Empagliflozin low dose, Empagliflozin high dose
- Where
- 92 sites in United States
- Volunteers
- 166 people
- Sponsor
- Boehringer Ingelheim
Breastfeeding, Exclusive Breastfeeding
KULEA-NET: A Mobile Application for African American/Black Mothers to Promote Exclusive and Continuous Breastfeeding
KULEA-NET is a mHealth intervention that will improve knowledge, self-efficacy, and intentions related to exclusive breastfeeding (EBF).
- Trial name
- KULEA-NET (NCT05985876)
- Testing
- KULEA-NET application, Control Group: Usual Care
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Benten Technologies, Inc.
Hepatitis C
BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C
The purpose of this study is to compare the rates of sustained virologic response in each cohort (Black-African Americans, Latinos) in this study to historical rate.
- Trial name
- NCT01389323
- Testing
- Daclatasvir, Peg-Interferon Alfa-2a, Ribavirin
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 448 people
- Sponsor
- Bristol-Myers Squibb
HIV-1 Infection
Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
The primary objective of this study is to evaluate the efficacy of switching from a regimen of 2 nucleos(t)Ide reverse transcriptase inhibitors (NRTIs) and a third agent to a fixed dose combination (FDC) of…
- Trial name
- BRAAVE 2020 (NCT03631732)
- Testing
- B/F/TAF, NRTIs, Third Agent
- Where
- 82 sites in United States
- Volunteers
- 496 people
- Sponsor
- Gilead Sciences
Congestive Heart Failure
African-American Heart Failure Trial
A placebo-controlled trial of BiDil added to standard therapy in African-American patients with heart failure.
- Trial name
- NCT00047775
- Testing
- BiDil
- Where
- 7 sites in United States
- Volunteers
- 1,100 people
- Sponsor
- Nitromed